In the last trading session, 1.24 million Athira Pharma Inc (NASDAQ:ATHA) shares changed hands as the company’s beta touched 2.99. With the company’s per share price at $0.65 changed hands at -$0.01 or -2.03% during last session, the market valuation stood at $22.00M. ATHA’s last price was a discount, traded about -561.54% off its 52-week high of $4.30. The share price had its 52-week low at $0.41, which suggests the last value was 36.92% up since then. When we look at Athira Pharma Inc’s average trading volume, we note the 10-day average is 27.43 million shares, with the 3-month average coming to 5.04 million.
Analysts gave the Athira Pharma Inc (ATHA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATHA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Athira Pharma Inc’s EPS for the current quarter is expected to be -0.45.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Athira Pharma Inc (NASDAQ:ATHA) trade information
Instantly ATHA was in red as seen at the end of in last trading. With action 1.03%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -73.40%, with the 5-day performance at 1.03% in the green. However, in the 30-day time frame, Athira Pharma Inc (NASDAQ:ATHA) is 55.37% up. Looking at the short shares, we see there were 1.56 million shares sold at short interest cover period of 2.74 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18, meaning bulls need an upside of 96.39% from its current market value. According to analyst projections, ATHA’s forecast low is 3 with 33 as the target high. To hit the forecast high, the stock’s price needs a -4976.92% plunge from its current level, while the stock would need to soar -361.54% for it to hit the projected low.
Athira Pharma Inc (ATHA) estimates and forecasts
Data shows that the Athira Pharma Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -72.01% over the past 6 months, a 16.83% in annual growth rate that is considerably higher than the industry average of 16.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -81.69%. The 2024 estimates are for Athira Pharma Inc earnings to increase by 19.09%.
ATHA Dividends
Athira Pharma Inc is expected to release its next quarterly earnings report in December.
Athira Pharma Inc (NASDAQ:ATHA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.95% of Athira Pharma Inc shares while 62.14% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 63.38%. There are 62.14% institutions holding the Athira Pharma Inc stock share, with PERCEPTIVE ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 14.099% of the shares, roughly 5.4 million ATHA shares worth $14.32 million.
BAKER BROS. ADVISORS LP holds the second largest percentage of outstanding shares, with 8.2298% or 3.15 million shares worth $8.36 million as of 2024-06-30.
